All Videos

Joe Monroe, MPAS, PA, share details from his presentation at the 2022 SDPA Annual Summer Meeting regarding his 36 years of encounters with the legal profession as a dermatology physician assistant.

Joe Monroe, MPAS, PA, sits down with Dermatology Times® to discuss his recent presentation on using your cell phone to your advantage in your dermatology practice at the 2022 SDPA Annual Summer Meeting held in Austin, Texas.

Clinicians can sometimes encounter situations that fall outside the dermatology realm. Melissa Mauskar, MD, explains how to navigate through these difficult conversations and situations in a video interview with Dermatology Times®.

Lisa Swanson, MD, sits down to discuss her recent presentation on pediatric dermatology featured at the 2022 SDPA Annual Summer Meeting held June 16-19, 2022, in Austin, Texas. She also describes her experience being the only pediatric dermatologist in Idaho.

Travis Vandergriff, MD, details information every physician assistant should know regarding inflammatory skin diseases during his presentation at the 2022 SDPA Annual Summer Meeting held June 16-19, 2022, in Austin, Texas.

In this video interview, Jean Bolognia, MD, discusses her recent presentation at the 2022 Society of Dermatology Physician Assistants Annual Summer Meeting regarding how to identify the various cutaneous manifestations of lupus.

Lindsey Savickas, RN, BSN, and COO at Infusion Associates, explains how infusion centers can support researchers in the dermatology space in discovering more effective treatments.

Barbara McElroy, MSN, CRNI, VA-BC, explains the responsibility a nurse has to their patient and how the Nurse Practicing Act needs to be more well-known.

Joe Monroe, MPAS, PA, details how he helped found the Society of Dermatology Physician Assistants and reflects on the opposition they encountered along the way.

Robert Dracker, MD, MHA, MBA, CPI, medical director of Summerwood Pediatrics & Infusacare Medical Services, sits down to discuss why choosing an infusion center with pediatric experience will improve treatment outcomes.

Lindsey Savickas, RN, BSN, and COO at Infusion Associates, explains how infusion centers and dermatologists are going to work together more as medications become more advanced.

Brian Nyquist, MPH, the CEO of the National Infusion Center Association (NICA), talks on the engaging sessions happening this weekend at the NICA conference and its growing importance to the dermatology community.

In this week’s Pointers with Dr Portela, the 208SkinDoc talks a case of a man who received a chemical peel that went wrong.

In this week’s Pointers with Dr Portela, the 208SkinDoc talks about the end of Melanoma Awareness Month and gives advice on how to prevent skin cancer.

Joshua Zeichner, MD, discusses how important it is to treat acne properly and gives a tip about moisturizers and topical retinoids.

Darrell S. Rigel, MD, MS, FAAD, answers the question of what is up coming in the world of dermatology in the way of precision medicine.

In a video with Dermatology Times®, James Q. Del Rosso, DO, discusses his presentation “What’s News in the Medicine Chest” at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs.

Will drinking caffeinated coffee reduce skin cancer risk? Is gene expression profiling set to become mainstream testing for melanoma? See what Darrell S. Rigel, MD, MS, FAAD, has to say.

Darrell S. Rigel highlights what to expect for the 2022 Fall Clinical Dermatology Conference for PAs & NPs happening June 3 to 5 in Scottsdale, Arizona.

In this drug pipeline interview, Christopher Bunick, MD, PhD, discusses what is innovative in future acne treatment options, what research is happening, and what potential approvals the dermatology space has to look forward to.

In this week’s Pointers with Dr Portela, the 208SkinDoc dives into the reason why his channel exists and how he plans to help the average patient watching his YouTube videos.

In this week’s Pointers with Dr Portela, the 208SkinDoc hosts a podcast called, “Between Two Derms.” This week he covers cases in the clinic, psoriasis at the Met Gala and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc has posted several YouTube shorts on sunscreen. See what pearls he had to share on protecting skin from the sun.

Among other things, it is about what happens before the scalpel that Ann W. Silk, MD, MS would like to see more research into advanced BCC treatment. Neoadjuvant therapies show promise in helping patients avoid or downgrade surgery, as she explains here. Silk also delves into other areas of research that offer new potential for treating advanced BCC.

Is timing everything? Chrysalyne D. Schmults, MD, FAAD looks to a future where clinicians have a better understanding of the “how” and “when” of using hedgehog inhibitors and anti-PD1 medication. Here are the questions she’d like to see answered in upcoming research.

Darrell S. Rigel, MD, MS, FAAD vision of the future treatment innovations for would include medications based on better-targeted immune pathways, effective ways to treat metastatic BCC, and a vaccine to prevent advanced BCC from developing. Rigel addresses these and other developments he sees or would like to see on the horizon.

In the world of medical oncologist Ann W. Silk, MD, MS a 30% response rate can be good news. So can drugs that can limit side effects to address a discontinuation rate that may be as high as 30%. Silk discusses the mechanisms of action of existing and new tools, such as immunotherapy, and recommendations for how physicians can maximize their effectiveness in a clinical setting.

Chrysalyne D. Schmults, MD, provides talking points on assessing which patients are ideal candidates for surgery and, when surgery is not an option, matching medications to the needs and quality of life concerns for the individual patient. She offers best-practice guidance for optimizing treatment choices that address challenges surrounding extended durability, reduction of adverse effects, and improvement in rates of occurrence of progression.

Darrell S. Rigel, MD, talks through the pros, cons, and unknowns of established medications such as Hedgehog inhibitors and newly FDA-approved drugs such as cemiplimab (Libtayo; Sanofi and Regeneron Pharmaceuticals). Get the latest on dosing, drug holidays, tolerability, and long-term disease management.

What risks do patients with the highest stage advanced BCC have for metastasis or death? Chrysalyne D. Schmults, MD, and her team at Brigham and Women’s Hospital in Boston, Massachusetts, developed a new staging system to help answer that question. Here, she shares insights on tumor classification, its implication for treatment, and the ground rules for creating an effective tumor review board.